Pharmacokinetics and pharmacodynamics of beta blockers in heart failure

Heart Failure Reviews

Volumn 9, Issue 2, 2004, Pages 131-137

  Talbert, Robert L ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Beta blockers; Metabolism; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA 1 ADRENERGIC RECEPTOR; AMIODARONE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CELECOXIB; CYTOCHROME P450 2D6; DIGITALIS; DIPHENHYDRAMINE; FLUOXETINE; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; PLACEBO; QUINIDINE;

ADRENERGIC RECEPTOR BLOCKING; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; HEART FAILURE; HUMAN; MORBIDITY; MORTALITY; PHARMACODYNAMICS; SIDE EFFECT; SUSTAINED RELEASE FORMULATION;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE, CONGESTIVE; HUMANS; METOPROLOL; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 8444222708     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:HREV.0000046368.08825.20     Document Type: Article

References (50)

1. Patterson JH, Rodgers JE. Expanding role of beta-blockade in the management of chronic heart failure. Pharmacotherapy 2003 23:451-459.
2. Mann DL. Mechanisms and models in heart failure: A combinatorial approach. Circulation 1999;100:999-1008.
3. Hunt SA, Baker DW, Chin ME, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Journal of the American College of Cardiology 2001;38:2101-2113.
4. Remme WJ, Swedberg K, European Society of C. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. European Journal of Heart Failure 2002;4:11-22.
5. Anonymous. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. [erratum appears in J Card Fail 2000;6(1):74]. Journal of Cardiac Failure 1999;5:357-382.
6. Foody JM, Farrell MH, Krumholz HM. Beta-Blocker therapy in heart failure: Scientific review. JAMA 2002;287:883-889.
7. Anonymous. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.
8. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. New England Journal of Medicine 2001;344:1651-1658.
9. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-2199.
10. Anonymous. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
11. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295-1302.
12. Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release/extended release in patients with severe heart failure: Analysis of the experience in the MERIT-HF study. Journal of the American College of Cardiology 2001;38:932-938.
13. Cleland JG. Beta-blockers for heart failure: Why, which, when, and where. Medical Clinics of North America 2003;87:339-371.
14. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998;280:623-629.
15. Ko D, Hebert PR, Coffey CS, Curtis JP, et al. Adverse effects of b-blocker therapy for patients with heart failure. A quantitative overview of randomized trials. Archives of Internal Medicine 2004 164:1389-1394.
16. Bristow MR. beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-569.
17. Yuan Z, Shioji K, Kihara Y, Takenaka H, Onozawa Y, Kishimoto C. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: Anti-inflammatory effects associated with antioxidant property. American Journal of Physiology - Heart&Circulatory Physiology 2004 286:H83-H90.
18. Bristow MR, Feldman AM, Adams KF, Jr., Goldstein S. Selective versus nonselective beta-blockade for heart failure therapy: Are there lessons to be learned from the COMET trial? Journal of Cardiac Failure 2003;9:444-453.
19. Azevedo ER, Kubo T, Mak S, et al. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: Differential effects on sympathetic activity. Circulation 2001 104:2194-2199.
20. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-2825.
21. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645-2651.
22. Hryniewicz K, Androne AS, Hudaihed A, Katz SD. Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure. Circulation 2003;108:971-976.
23. Hirooka K, Yasumura Y, Ishida Y, et al. Comparative left ventricular functional and neurohumoral effects of chronic treatment with carvedilol versus metoprolol in patients with dilated cardiomyopathy. Japanese Circulation Journal 2001;65:931-936.
24. Sanderson JE, Chan SK, Yip G, et al. Beta-blockade in heart failure: A comparison of carvedilol with metoprolol. Journal of the American College of Cardiology 1999;34:1522-1528.
25. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003;362:7-13.
26. Dargie HJ. Beta blockers in heart failure. Lancet 2003;362:2-3.
27. Mann DL, Deswal A. Angiotensin-receptor blockade in acute myocardial infarction - a matter of dose. New England Journal of Medicine 2003;349:1963-1965.
28. ThaBani U. Assessment of "oPtimal" beta blockade in treating patients with angina pectoris. Acta Medica Scandinavica-Supplementum 1985 694:178-187.
29. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-1446.
30. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. New England Journal of Medicine 1996;334:1349-1355.
31. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807-2816.
32. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. American Journal of Medicine 2002;113:650-656.
33. Tzivoni D, Medina A, David D, Barzilai Y, Brunel P. Effect of metoprolol in reducing myocardial ischemic threshold during exercise and during daily activity. American Journal of Cardiology 1998 81:775-777.
34. Sandberg A, Ragnarsson G, Jonsson UE, Sjogren J. Design of a new multiple-unit controlled-release formulation of metoprolol - metoprolol CR. European Journal of Clinical Pharmacology 1988;33:S3-S7.
35. Sandberg A, Blomqvist I, Jonsson UE, Lundborg P. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: A comparison with conventional tablets. European Journal of Clinical Pharmacology 1988;33:S9-S14.
36. Wikstrand J, Andersson B, Kendall MJ, Stanbrook H, Klibaner M. Pharmacokinetic considerations of formulation: Extended-release metoprolol succinate in the treatment of heart failure. Journal of Cardiovascular Pharmacology 2003;41:151-157.
37. Sandberg A, Abrahamsson B, Regardh CG, Wieselgren I, Bergstrand R. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: A review article. Journal of Clinical Pharmacology 1990;30:S2-S16.
38. Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clinical Pharmacology&Therapeutics 2003;74:130-137.
39. Hamelin BA, Bouayad A, Methot J, et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clinical Pharmacology&Therapeutics 2000;67:466-477.
40. Rau T, Heide R, Bergmann K, et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002;12:465-472.
41. Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clinical Pharmacology&Therapeutics 2002;72:429-437.
42. Lucker P, Moore G, Wieselgren I, Olofsson B, Bergstrand R. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. Journal of Clinical Pharmacology 1990;30:S17-S27.
43. Andersson B, Aberg J, Lindelow B, Tang MS, Wikstrand J. Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure. Journal of Cardiac Failure 2001;7:311-317.
44. Neugebauer G, Akpan W, von Mollendorff E, Neubert P, Reiff K. Pharmacokinetics and disposition of carvedilol in humans. Journal of Cardiovascular Pharmacology 1987;10:S85-S88.
45. Tenero D, Boike S, Boyle D, et al. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. Journal of Clinical Pharmacology 2000;40:844-853.
46. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype - a major determinant of metoprolol metabolism and response. New England Journal of Medicine 1982;307:1558-1560.
47. Zhou HH, Wood AJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clinical Pharmacology&Therapeutics 1995;57:518-524.
48. Stoschitzky K, Koshucharova G, Lercher P, et al. Stereoselective effects of (R)- and (S)-carvedilol in humans. Chirality 2001 13:342-346.
49. Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clinical Pharmacology&Therapeutics 1983;34:732-737.
50. Silas JH, McGourty JC, Lennard MS, Tucker GT, Woods HE Polymorphic metabolism of metoprolol: Clinical studies. European Journal of Clinical Pharmacology 1985;28:85-88.